Abstract：Objective: To explore the efficacy predictors to percutaneous coronary intervention for the patients with Ischemic cardiomyopathy(ICM). Methods: 123 patients with ICM admitted in the Chengde Central Hospital from Sep,2015 to Sep,2017 underwent coronary angiography and PCI. The basic data and interventional data of the patients were collected and followed up for 6 months. The changes of various indexes before and after PCI were analyzed. Based on whether the treatment is effective, the patients were divided into two groups. Through the comparison between groups, the efficacy predictors to percutaneous coronary intervention for the patients with ICM were analyzed. Result:Among the 123 ICM patients enrolled in the study, 67 were PCI-responder and 56 were non-PCI-responder , with an effective rate of 54.47%. There were no statistically significant differences in general data between the two groups. And there were 7 indicators including sex, age, diabetes, SYNTAX score, angina pectoris, electrocardiogram V1~V4 lead Q wave, and whether left anterior descending coronary artery revascularization were correlated to the efficacy of PCI for the patients with ICM. Multivariable Logistic regression analysis showed that age(OR=0.825, 95% CI:0.813~1.157,P=0.032), diabetes(OR=0.170, 95% CI:0.042~0.643, P=0.012), angina pectoris(OR=3.982, 95% CI:0.581~14.232, P=0.008), electrocardiogram V1~V4 lead Q wave(OR=0.039, 95% CI:0.018~0.576,P=0.000), the left anterior descending coronary artery effective revascularization(OR=4.251, 95% CI:0.833~19.143,P=0.046) were the pridictors to percutaneous coronary intervention for the patients with Ischemic cardiomyopathy. Conclusion: The younger age, without diabetes mellitus, angina pectoris, electrocardiogram V1~V4 lead without Q waves, and left anterior descending coronary artery revascularization are predictors of possible benefit from PCI in patients with ICM.
[1] Gheorghiade M,Sopko G,de Luca L,et al. Navigating the crossroads of coronary artery disease and heart failure[J]. Circulation,2006,114: 1202~1213. [2] Yancy CW,Jessup M,Bozkurt B,et al. 2017 ACCF/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure:a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of American[J]. Circulation,2017,136(6):e137~161. [3] Expert Panel on Detection.Evaluation and treatment of High blood cholesterol in adults.Executive summary of the third report of The Nation Cholesterol Education Program(NCEC)expert panal on detection,evaluation and treatment of High Blood cholesterol in adults(Adult Treatment Panel[J].JAMA,2001,285(19):2486~2497. [4] 韩雅玲,王海昌,陈韵岱,等.急性ST段抬高心肌梗死病人院内死亡发生率的相关因素分析:冠心病介入治疗数据库资料[J].解放军医学杂志,2015,40(4):262~265. [5] 赵雅雯,郑杨.急性ST段抬高型心肌梗死短期预后的影响因素[D].长春:吉林大学,2015. [6] J.V.John,Murray M,Adamopoulos S,et al. 2012ESC guideline for the diognosis and treatment of acute and chronic heart failure[J].Eur Heart, 2012,33: 1787~1847. [7] Yancy CW,Jessup M,Bozkurt B,et al. 2013 ACCF/AHA guideline for the management of heart failure[J].Am Coll Cardiol,2013,62: e147~e239. [8] Windecker S,Kolh P,Alfonso F,et al. 2014 ESC/EACTS guidelines on myocardial revascularization[J]. Eur Heart,2014,35: 2541~2619.
2018, Vol. 24 
冀公网安备13080202000677号